Experience
Our Expertise in 3 Core Service Areas
We support our clients’ businesses through three core areas of service.
Quantitative Research
Quantitative research is our first love at euPlexus, and our team brings decades of experience stretching the boundaries of quantitative research design through application of scientific principles and trends.
Our quantitative work is centered in:
- Demand/forecasting and market evolution
- Market landscape & opportunity assessment
- Segmentation & customer stratification
- Message impact & behavior change
Qualitative Research
With our heavy emphasis on language modeling and psychometrics, we also place high value on qualitative insight mining.
Our seasoned moderators focus on a range of project types, including:
- Product/TPP reactions & uptake intent
- Opportunity assessment & market evaluation
- Message refinement & language framing
- Positioning evolution & validation
Brand Consulting
euPlexus is deeply committed to helping our client and agency colleagues use the science of linguistics, persuasion and emotionality to create better marketing materials.
We offer consulting services in:
- Market opportunity consultation
- Matching messages to customer psychographics and needs
- Language framing & context-alignment
Our Therapeutic Expertise
The euPlexus team is primarily focused on supporting the needs of brands working in the areas of rare disease and oncology. We seek out clients who are working on the critical boundaries of medicine and underserved populations.
Our Expertise in Rare Disease
Each rare disease population represents its own unique recruiting challenge. But our wealth of experience across a huge variety of these conditions has given us a tool kit of tactics, methods and tips that have helped us succeed in building robust research platforms for understanding the unique needs and challenges of these disease settings.
RARE DISEASES/CONDITIONS
WIDE RANGE OF RARE DISEASES, INCLUDING BLEEDING DISORDERS, NEUROLOGICAL, AND AUTOMIMMUNE
Atypical Hemolytic Uremic Syndrome (aHUS)
Alopecia Areata
Antibody-Mediated Rejection (AMR) in Organ Transplant
Cerebral Palsy
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Cytomegalovirus (CMV) in Organ Transplant
Dravet Syndrome (DS)
Dupuytren’s Contracture
Fragile X Syndrome (FXS)
Gaucher Disease
Graft versus Host Disease (GvHD – acute/chronic)
Guillain-Barre Syndrome (GBS)
Hereditary Angioedema (HAE)
Hemophilia A (Acquired and Non-Acquired)
Hemophilia B
Hemophilia with Inhibitors (CHAwI)
Hunter Disease
Huntington’s Disease / Huntington’s chorea
Lennox-Gastaut Syndrome (LGS)
Myasthenia Gravis (gMG)
Neurofibromatosis Type 1 (NF1)
Niemann-Pick Disease Type C (NPC)
Pompe Disease
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Plexiform Neurofibromas (PN)
Primary/Secondary Immunodeficiency Disorder (PIDD/SIDD)
Protein C deficiency
Sickle Cell Disease (SCD)
Systemic Lupus Erythematosus (SLE)
Thyroid Eye Disease (TED)
Thrombotic Thrombocytopenic Pupura (TTP – acquired/ hereditary)
Tourette’s Syndrome
Von Willebrand Disease (Type 2 & Type 3)
Warm Autoimmune Hemolytic Anemia (WAIHA)
MARKET/THERAPEUTIC CONTEXTS
ACROSS VARIOUS MARKET CONTEXTS
Therapeutic Forms/Administration Routes:
Oral, Topical, Intrathecal, IV, SubQ,
Complex delivery systems, Self vs. HCP-Admin
Traditional and Novel Classes of Therapy:
Immunoglobulin, Immunosuppressants,
Factor Therapy, Biologics/Monoclonal antibodies,
Gene therapy
Nature of Disease:
Lifestyle/Cosmetic, Acute and Chronic,
Highly Urgent and Less Urgent,
Aggressive/Degenerative, High and Low Mortality
Treatment Options
None approved/All off-label vs. 1-2
Approved options vs. Several approved options
Diagnosis/Detection Process
Extremely challenging/specialized diagnosis vs.
More standardized approach
Treatment Approach
Highly Variable → Some Mix → Standardized
Our Expertise in Oncology
Our Oncology experience is both deep and broad, spanning across multiple tumor types, classes of therapies, and market types. Here at euPlexus, Oncology is one of our core passions and we believe there is no other therapeutic market like it. The rapid scientific discovery and development, constant dynamism, and most importantly, the end goal of extending human life – it is inherently a human obligation to invest ourselves in the world of Oncology
TUMOR TYPES
SOLID TUMORS
- Breast
- Lung (NSCLC and SCLC)
- Gastric
- Colorectal
- Glioblastoma
- Endometrial
- Ovarian
- Urothelial
- Prostate (mCRPC)
- Head & Neck Cancers
LIQUID TUMORS
- Acute Myeloid Leukemia (AML)
- Multiple Myeloma (MM)
- Myelodysplastic Syndrome (MDS)
- Non-Hodgkin Lymphoma (NHL)
CLASSES OF THERAPY
TRADITIONAL AND NOVEL CLASSES
- ADCs
- Bispecific Antibodies
- CAR-T-Cell therapies/Cell therapy
- Chemotherapy
- Hormonal therapies (oral SERDs, endocrine therapies, androgen deprivation therapy, etc.)
- IOs/Immunotherapies/ICIs/TIGITs
- Immunomodulatory therapies
- Monoclonal Antibodies
- Proteasome Inhibitors
- Radiopharmaceutical therapies
- Tyrosine Kinase/Multi-Kinase Inhibitors (TKIs, small molecule, etc.)
MARKET SITUATIONS/TYPES
ACROSS MARKET SPECTRUMS
# of Options:
None → Some → Extremely Crowded
Class Maturation:
1st in-Class → 2nd in-Class → 3rd+ in-Class
Unmet Need:
High → Medium → Low
Treatment Approach:
Highly Variable → Some Mix → Standardized
Competitive Dynamics (Market Leader Presence):
None → Some → Entrenched Market Leader
Target Subpopulation Prevalence:
Extremely Rare → Medium → More Common
Customer Populations
Stakeholders
Our team has studied, interviewed and recruited diverse stakeholder populations related to your marketing efforts, including
- Treating physicians, including a wide range of specialists who manage rare patient populations
- Thought leaders
- Patients & their caregivers
- Nurses, physician assistants and other members of the integrated care team
- Practice administrators, office administrators and corporate decision makers
Special Populations
Additionally, we have experience in recruiting diverse and unique sub-populations.
- Non-dominant languages
- Demographic & cultural minorities
- Behaviorally/cognitively impaired cohorts & minorities
- Functionally impaired sub-populations
- Protected groups, including people with disabilities and pediatric groups
Global Reach
Our senior team has led evidence-based consulting and market research across the globe, and our network of trusted recruiting, moderating, analytics and compliance partners across the world ensure that our work is contextualized to the market/community in question.